Last reviewed · How we verify
Multitargeted Tyrosine Kinase Inhibitor PLX3397 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Multitargeted Tyrosine Kinase Inhibitor PLX3397 (Multitargeted Tyrosine Kinase Inhibitor PLX3397) — Barbara Ann Karmanos Cancer Institute.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Multitargeted Tyrosine Kinase Inhibitor PLX3397 TARGET | Multitargeted Tyrosine Kinase Inhibitor PLX3397 | Barbara Ann Karmanos Cancer Institute | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Multitargeted Tyrosine Kinase Inhibitor PLX3397 CI watch — RSS
- Multitargeted Tyrosine Kinase Inhibitor PLX3397 CI watch — Atom
- Multitargeted Tyrosine Kinase Inhibitor PLX3397 CI watch — JSON
- Multitargeted Tyrosine Kinase Inhibitor PLX3397 alone — RSS
Cite this brief
Drug Landscape (2026). Multitargeted Tyrosine Kinase Inhibitor PLX3397 — Competitive Intelligence Brief. https://druglandscape.com/ci/multitargeted-tyrosine-kinase-inhibitor-plx3397. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab